ESP Pharma Acquires Exclusive North American Rights to Retavase

ESP Pharma, a niche pharmaceutical company focused on the acquisition, marketing and late-stage development of life-saving acute-care therapeutics, has announced the acquisition, by ESP Pharma, of U.S. and Canadian rights to Retavase (reteplase) from Centocor, a biopharmaceutical operating company of Johnson & Johnson. Scios, another Johnson & Johnson company, currently markets the product on behalf of Centocor.

BioSpace (http://home.businesswire.com/portal/site/biospace/index.jsp?epi-content=GENERIC&newsId=20050201005378&ndmHsc=v2*A1106658000000*B1107296461000*DgroupByDate*J2*N1000122&newsLang=en&beanID=1229976837&viewID=news_view)